Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CFO Kenneth Myszkowski sold 16,104 shares of the company's stock on January 5, 2024, according to a SEC Filing.
SOUTH SAN FRANCISCO, Calif., January 03, 2024 Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
The global RNA therapeutics market is driven by the increasing number of government initiatives for large-scale sequencing projects, target specificity, and selectivity of treatment.Wilmington, Delaware, Nov. 15, 2023 (GLOBE NEWSWIRE) Allied Market Research published a report, titled, “RNA Based Therapeutics Market by Disease Type (RNA antisense and RNA interference (RNAi)), Application (Auto-Immune Disorders and Genetic Disorders) and End User (Hospitals & Clinics and Research Institutes): G